Lates News

According to the AI flash news, Dongwu Securities released a research report on April 27th, giving Fosun Pharmaceutical (603998.SH) a "buy" rating. The main reasons for the rating include: 1) Optimization of core product structure, with high gross profit growth driven by cardiovascular and orthopedic departments; 2) Continuous improvement of profitability, significant results driven by innovation. (Daily Economic News)